Volume 1, Issue 1 (August 2022)
Health Science Monitor 2022, 1(1): 1-9 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Kazempour Dizaji M, Varahram M, Roozbahani R, Abedini A, Zare A, Kiani A, et al . Simulation of COVID-19 disease epidemic in Iran based on SIR model. Health Science Monitor 2022; 1 (1) :1-9
URL: http://hsm.umsu.ac.ir/article-1-49-en.html
URL: http://hsm.umsu.ac.ir/article-1-49-en.html
Mehdi Kazempour Dizaji * 
, Mohammad Varahram , Rahim Roozbahani , Atefe Abedini , Ali Zare , Arda Kiani , Mohammad Ali Emamhadi , Niloufar Alizedeh Kolahdozi , Syeyd Alireza Nadji , Majid Marjani
, Mohammad Varahram , Rahim Roozbahani , Atefe Abedini , Ali Zare , Arda Kiani , Mohammad Ali Emamhadi , Niloufar Alizedeh Kolahdozi , Syeyd Alireza Nadji , Majid Marjani
Mycobacteriology Research Center (MRC),National Research Institute of Tuberculosis and Lung Disease (NRITLD) , Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract: (867 Views)
Background & Aims: The spread of the COVID-19 virus is currently considered the most important global health challenge. Therefore, it is very important to study and simulate the patterns of spread of this disease based on mathematical models. This study aimed to simulate the COVID-19 epidemic based on the SIR model, in Iran.
Materials & Methods: In this study, the COVID-19 epidemic was simulated based on the susceptible-infected-recovered (SIR) mathematical model. According to the parameters of this model, different scenarios for this disease were examined. Finally, the simulation of the COVID-19 epidemic based on the values of these parameters was presented for Iran.
Results: According to the results of this study, with increasing the level of social restrictions and health measures, the reproductive rate of COVID-19 decreased, and also with access to effective medicines and vaccines, the recovery rate of this disease increased, and fewer people became infected. Moreover, results showed that with the continuation of social restrictions and attention to health issues by the people in Iran, the peak of COVID-19 is seen within 50 days from the beginning of the epidemic also about 5% of the population is affected by this disease. The end of the initial wave of the disease was predicted at least 100 days after the onset of the epidemic.
Conclusion: A simulation study to evaluate the prevalence of COVID-19 will provide comprehensive and complete information about the role of health care measures and social restrictions to prevent the spread of this disease to health researchers.
Materials & Methods: In this study, the COVID-19 epidemic was simulated based on the susceptible-infected-recovered (SIR) mathematical model. According to the parameters of this model, different scenarios for this disease were examined. Finally, the simulation of the COVID-19 epidemic based on the values of these parameters was presented for Iran.
Results: According to the results of this study, with increasing the level of social restrictions and health measures, the reproductive rate of COVID-19 decreased, and also with access to effective medicines and vaccines, the recovery rate of this disease increased, and fewer people became infected. Moreover, results showed that with the continuation of social restrictions and attention to health issues by the people in Iran, the peak of COVID-19 is seen within 50 days from the beginning of the epidemic also about 5% of the population is affected by this disease. The end of the initial wave of the disease was predicted at least 100 days after the onset of the epidemic.
Conclusion: A simulation study to evaluate the prevalence of COVID-19 will provide comprehensive and complete information about the role of health care measures and social restrictions to prevent the spread of this disease to health researchers.
Type of Study: Research |
Subject:
General
Received: 2022/07/12 | Accepted: 2022/08/14 | Published: 2022/08/20
Received: 2022/07/12 | Accepted: 2022/08/14 | Published: 2022/08/20
References
1. Roush S, Fast H, Miner CE, Vins H, Baldy L, McNall R, et al. National Center for Immunization and Respiratory Diseases (NCIRD) Support for Modernization of the Nationally Notifiable Diseases Surveillance System (NNDSS) to Strengthen Public Health Surveillance Infrastructure in the US. 2019 CSTE Annual Conference; 2019. [Google Scholar]
2. WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020 (Internet). (cited 2022 Aug 31). Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. [URL]
3. WHO. Director-General's remarks at the media briefing on 2019-nCoV on 10 February 2020 (Internet). (cited 2022 Aug 31). Available from: https://www.who.int/director general/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-10-february-2020. [URL]
4. Maitra S, Biswas M, Bhattacharjee S. Case-fatality rate in COVID-19 patients: a meta-analysis of publicly accessible database. medRxiv (Internet). 2020; Available from: https://www.medrxiv.org/content/10.1101/2020.04.09.20059683v2 [DOI]
5. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42. [DOI] [PMID]
6. Mahase E. Coronavirus: covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate. British Medical Journal Publishing Group; 2020. [DOI] [PMID]
7. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The lancet. 2020;395(10223):514-23. [DOI] [PMID]
8. Chen Y-C, Lu P-E, Chang C-S, Liu T-H. A time-dependent SIR model for COVID-19 with undetectable infected persons. IEEE Transactions on Network Science and Engineering. 2020;7(4):3279-94. [DOI]
9. Peng L, Yang W, Zhang D, Zhuge C, Hong L. Epidemic analysis of COVID-19 in China by dynamical modeling. arXiv preprint arXiv:200206563. 2020. [DOI]
10. Nesteruk I. Estimations of the coronavirus epidemic dynamics in South Korea with the use of SIR model. Preprint ResearchGate. 2020. [DOI] [PMCID]
11. Zhu K, Ying L. Information source detection in the SIR model: A sample-path-based approach. IEEE/ACM Transactions on Networking. 2014;24(1):408-21. [DOI]
12. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. New England journal of medicine (Internet). 2020; Available from: https://www.nejm.org/doi/full/10.1056/NEJMOa2001316 [DOI] [PMID] [PMCID]
13. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323(18):1775-6. [DOI] [PMID]
14. Battegay M, Kuehl R, Tschudin-Sutter S, Hirsch HH, Widmer AF, Neher RA. 2019-novel Coronavirus (2019-nCoV): estimating the case fatality rate-a word of caution. Swiss Med Wkly. 2020(5). [DOI]
15. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery. 2020;19(3):149-50. [DOI] [PMID]
16. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. The New England Journal of Medicine. 2020;382(18):1708-20. [DOI] [PMID] [PMCID]
17. Singh R, Adhikari R. Age-structured impact of social distancing on the COVID-19 epidemic in India. arXiv preprint arXiv:200312055. 2020. [Google Scholar]
18. Calafiore GC, Novara C, Possieri C. A Modified SIR Model for the COVID-19 Contagion in Italy. In: 2020 59th IEEE Conference on Decision and Control (CDC) (Internet). Jeju, Korea (South): IEEE [DOI]
19. 2020 (cited 2022 Aug 31). p. 3889-94. Available from: https://ieeexplore.ieee.org/document/9304142/. [URL]
20. Satsuma J, Willox R, Ramani A, Grammaticos B, Cârstea AS. Extending the SIR epidemic model. Physica A: Statistical Mechanics and its Applications. 2004;336(3-4):369-75. [DOI]
21. Atkeson A. What will be the economic impact of COVID-19 in the US? Rough estimates of disease scenarios. National Bureau of Economic Research; 2020. [DOI]
22. Lenka B. The mathematics of infectious disease (PhD Thesis). Comenius University Bratislava; 2007. [URL]
23. Rachah A, Torres DF. Mathematical modelling, simulation, and optimal control of the 2014 Ebola outbreak in West Africa. Discrete dynamics in nature and society (Internet). 2015;2015. Available from: https://www.hindawi.com/journals/ddns/2015/842792/ [DOI]
24. Simha A, Prasad RV, Narayana S. A simple stochastic sir model for covid 19 infection dynamics for karnataka: Learning from europe. arXiv preprint arXiv:200311920. 2020. [URL]
25. Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. Journal of Korean Medical Science. 2020;35(14). [DOI] [PMID] [PMCID]
26. Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA. 2020;323(16):1561-2. [DOI] [PMID]
27. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). BioScience Trends. 2020;14(1):69-71. [DOI] [PMID]
28. Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020;368(m1256). [DOI] [PMID]
29. Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020;323(14):1406-7. [DOI] [PMID] [PMCID]
30. Aslan IH, Demir M, Wise MM, Lenhart S. Modeling COVID‐19: Forecasting and analyzing the dynamics of the outbreaks in Hubei and Turkey. Mathematical Methods in the Applied Sciences. 2022;45(10):6481-94. [DOI]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
